Patients undergoing atrial fibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to ...

Compared with oral anticoagulant (OAC)-experienced patients, OAC-naïve patients received the same benefit in decreased bleeding risk with asundexian vs. apixaban but they were also less likely to ...

More patients who received the Watchman 2.5 device compared with the Amulet occluder device for left atrial appendage occlusion experienced high-risk device-related thrombi (DRTs), according to a ...

Transcatheter tricuspid valve replacement (TTVR) may be a "feasible and effective approach" for treating high-risk patients with severe tricuspid regurgitation (TR) who have limited therapeutic ...

An early one-time simultaneous measurement of LDL-C, high-sensitivity C-reactive protein (hsCRP) and lipoprotein(a) (Lp[a]) can independently predict long-term cardiovascular risk, according to a ...

Data from ACC's CathPCI Registry suggest a "favorable safety profile" for use of coronary intravascular lithotripsy (IVL) in treating patients presenting with acute coronary syndromes (ACS), according ...

A survey of over 2,000 geographical areas of Australia paired with future projections found that growing temperatures will exacerbate the country's burden of cardiovascular disease, according to new ...

Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement (SAVR) in women with severe aortic stenosis (AS), according to results from the RHEIA trial published ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

Join ACC's Prevention of Cardiovascular Disease Member Section this Wednesday, April 9 at 1 p.m. ET for a recap of ACC.25 prevention content and its influence on clinical practice. The webinar will ...

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...